Advanced search
Publication Cover
Current Medical Research and Opinion Volume 36, 2020 - Issue 8
Submit an article Journal homepage
4,209
Views
27
CrossRef citations to date
0
Altmetric
Metabolic Disease

Prevalence and economic burden of hyperkalemia in the United States Medicare population

Fan MuAnalysis Group, Inc, Boston, MA, USA; Correspondence[email protected]
,
Keith A. BettsAnalysis Group, Inc, Boston, MA, USA;
,
J. Michael WoolleyAstraZeneca, Wilmington, DE, USA
,
Akanksha DuaAnalysis Group, Inc, Boston, MA, USA;
,
Yao WangAnalysis Group, Inc, Boston, MA, USA;
,
Jia ZhongAnalysis Group, Inc, Boston, MA, USA;
&
Eric Q. WuAnalysis Group, Inc, Boston, MA, USA;
show all
Pages 1333-1341 | Received 12 Nov 2019, Accepted 17 May 2020, Published online: 12 Jun 2020

References

  • Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol. 2009;71:381–401.
  • Luo J, Brunelli SM, Jensen DE, et al. Association between serum potassium and outcomes in patients with reduced kidney function. CJASN. 2016;11(1):90–100.
  • Mushiyakh Y, Dangaria H, Qavi S, et al. Treatment and pathogenesis of acute hyperkalemia. Journal of Community Hospital Internal Medicine Perspectives. 2012;1(4):7372.
  • Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510–1513.
  • Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12(10):646–656.
  • Kovesdy CP. Epidemiology of hyperkalemia: an update. Kidney Int Suppl (2011). 2016;6(1):3–6.
  • Kovesdy CP. Updates in hyperkalemia: outcomes and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):41–47.
  • Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol. 1995;6(4):1134–1142.
  • Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212–S20.
  • Fitch K, Woolley JM, Engel T, et al. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202–210.
  • Betts KA, Woolley JM, Mu F, et al. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971–978.
  • Kim K, Thomsen RW, Nicolaisen SK, et al. Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study. BMJ Open. 2019;9(4):e026465
  • Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6(4):272–280.
  • Raebel MA, Ross C, Xu S, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25(4):326–333.
  • Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. CJASN. 2010;5(3):531–548.
  • Betts KA, Woolley JM, Mu F, et al. The Cost of Hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–393.
  • Dunn JD, Benton WW, Orozco-Torrentera E, et al. The burden of hyperkalemia in patients with cardiovascular and renal disease. The American journal of managed care. Am J Manag Care. 2015;21(15 Suppl):s307–s315.
  • Fleet JL, Shariff SZ, Gandhi S, et al. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012;2(6):e002011.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.